Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4.

2.

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis.

Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HW, Willebrords R, Poncelet A, Guillemont J, Bald D, Andries K.

J Biol Chem. 2008 Sep 12;283(37):25273-80. doi: 10.1074/jbc.M803899200. Epub 2008 Jul 14.

3.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K.

J Med Chem. 2008 Feb 28;51(4):875-96. doi: 10.1021/jm701284j. Epub 2008 Feb 7.

PMID:
18254606
4.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.

Bonfanti JF, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Janssens F, Sommen C, Wigerinck P, Andries K.

J Med Chem. 2007 Sep 20;50(19):4572-84. Epub 2007 Aug 28.

PMID:
17722899
5.

Diarylquinolines target subunit c of mycobacterial ATP synthase.

Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K.

Nat Chem Biol. 2007 Jun;3(6):323-4. Epub 2007 May 13.

PMID:
17496888
6.

Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.

Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, Janssens F, Wyde PR.

Antiviral Res. 2003 Nov;60(3):209-19.

PMID:
14638397
7.

In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.

Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA.

Antimicrob Agents Chemother. 1992 Jan;36(1):100-7.

8.

A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.

Andries K, Dewindt B, Snoeks J, Willebrords R, Stokbroekx R, Lewi PJ.

Antiviral Res. 1991 Oct;16(3):213-25.

PMID:
1666824
9.

Erbulozole (P.I.N.N.) (R 55 104) encapsulated into cyclodextrins: has it a combined antitumoral and radioprotective potential?

Distelmans W, Van Ginckel R, Vanherck W, Willebrords R, Wouters L, De Brabander M, Mesens J.

Anticancer Res. 1991 Jan-Feb;11(1):253-6.

PMID:
2018359
10.

Influence of the synthetic microtubule inhibitor erbulozole (P.I.N.N.) (R 55 104), a new tubulozole congener, and gamma irradiation on murine tumors in vivo.

Distelmans W, Van Ginckel R, Vanherck W, Willebrords R, De Brabander M, Wouters L, Heeres J.

Eur J Cancer Clin Oncol. 1989 Oct;25(10):1499-504.

PMID:
2591442
11.

Interaction between the microtubule inhibitor tubulozole and gamma-irradiation in murine tumors in vivo.

Distelmans W, Van Ginckel R, Vanherck W, Willebrords R, De Brabander M, Wouters L, Van den Winkel P, De Backer G.

Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):177-82.

PMID:
2912940
12.
13.

The kidney invasion test: its application to the Lewis lung carcinoma system.

Van Ginckel R, Vanherck W, Willebrords R, Distelmans W, De Brabander M.

Anticancer Res. 1986 Jul-Aug;6(4):705-8.

PMID:
3752948
14.

Tubulozole: a new stereoselective microtubule inhibitor.

De Brabander M, Geuens G, Nuydens R, Willebrords R, Moeremans M, Van Ginckel R, Distelmans W, Dragonetti C, Mareel M.

Ann N Y Acad Sci. 1986;466:757-66. No abstract available.

PMID:
3460448
15.

Microtubule dynamics during the cell cycle: the effects of taxol and nocodazole on the microtubule system of Pt K2 cells at different stages of the mitotic cycle.

De Brabander M, Geuens G, Nuydens R, Willebrords R, Aerts F, De Mey J.

Int Rev Cytol. 1986;101:215-74. No abstract available.

PMID:
2870994
16.

Effects of tubulozole on the microtubule system of cells in culture and in vivo.

Geuens GM, Nuydens RM, Willebrords RE, Van de Veire RM, Goossens F, Dragonetti CH, Mareel MM, De Brabander MJ.

Cancer Res. 1985 Feb;45(2):733-42.

17.

Microtubule dynamics and the mitotic cycle: a model.

De Brabander M, Aerts F, De Mey J, Geuens G, Moeremans M, Nuydens R, Willebrords R.

Basic Life Sci. 1985;36:269-78. No abstract available.

PMID:
3913416
18.

Microtubule stability and assembly in living cells: the influence of metabolic inhibitors, taxol and pH.

De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J.

Cold Spring Harb Symp Quant Biol. 1982;46 Pt 1:227-40. No abstract available.

PMID:
6125293
19.

Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores.

De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J.

Proc Natl Acad Sci U S A. 1981 Sep;78(9):5608-612.

20.

Microtubule assembly in living cells after release from nocodazole block: the effects of metabolic inhibitors, taxol and PH.

De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J.

Cell Biol Int Rep. 1981 Sep;5(9):913-20. No abstract available.

PMID:
6117376

Supplemental Content

Loading ...
Support Center